Follicular Lymphoma | Clinical

November 04, 2021

Mark J. Roschewski, MD, discusses standard of care options for the treatment of follicular lymphoma.

November 01, 2021

The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.

October 27, 2021

The FDA has accepted a biologics license application for tisagenlecleucel and granted it priority review as a potential treatment for relapsed or refractory follicular lymphoma after 2 lines of therapy

October 25, 2021

A significant proportion of patients worldwide live disease-free for a decade or longer following first-line therapy, with various approaches suggesting that there may be pathways to develop approaches for a cure for at least a subset of patients

October 14, 2021

Obinutuzumab is associated with greater toxicity compare to rituximab in follicular lymphoma.

October 11, 2021

An oncologist ruminates on emerging treatment options in follicular lymphoma and offers some clinical pearls.

October 11, 2021

Alan Skarbnik, MD, explains early relapse in follicular lymphoma and the available treatment options.

October 11, 2021

An expert describes typical monitoring strategies in follicular lymphoma.

October 11, 2021

Dr. Alan Skarbnik reviews the use of obinutuzumab-based therapies for follicular lymphoma and highlights data from a phase III study.

October 11, 2021

A key opinion leader discusses the considerations in choosing induction and maintenance therapy options for follicular lymphoma.